Table 3

The efficacy of H. pylori eradication or screen-and-eradication strategy in the risk reduction of gastric cancer: ongoing trials

Country registration number	Subjects/design	Experiment group	Control group	Primary outcome	Age (years)	Sample size/status	Start year/expected completion year
Effectiveness of H. pylori eradication
China/ChiCTR-TRC-10000979	Healthy subjects/double blind	Bismuth quadruple therapy	Bismuth + omeprazole + placebo	Gastric cancer incidence	25–54	94 101/recruitment completed	2011–2013/NA
Korea/NCT02112214	Healthy H. pylori infected subjects/double blind	Bismuth quadruple therapy	Placebo	Gastric cancer incidence	40–60	5224/recruitment completed	2014/2029
UK/NCT01506986	H. pylori-infected aspirin user/double blind	Triple therapy	Placebo	Peptic ulcer bleeding	≥60	3038/recruitment completed	2012/2021
Effectiveness of screening and eradication of H. pylori
UK/ISRCTN71557037	Healthy subjects/open label	H. pylori screening	No screening	Gastric cancer incidence and mortality	M: 35–69; F:45–69	56 000/recruitment completed	1997/2021
Taiwan/NCT01741363	Healthy subjects/open label	H. pylori screening and FIT	FIT alone	Gastric cancer incidence	50–69	60 000/recruitment completed	2014/2017
Latvia/NCT02047994	Healthy subjects/open label	H. pylori screening and FIT	FIT alone	Gastric cancer mortality	40–64	30 000/recruiting	2013/2033